Abbott Laboratories annual free cash flow for fiscal TTM was $7.4 billion, a decrease of 0.2% from $7.4 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $7.4B | $7.4B | $6.4B | $5.1B | $7.8B | $8.6B | $5.7B | $4.5B | $4.9B | $4.4B | $2.1B | $1.9B | $2.6B | $2.2B | $7.5B | $7.5B | $7.7B | $6.2B | $6.1B | $3.5B | $4.0B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $916M | $2.6B | $2.3B | $1.5B | $933M | $2.1B | $2.1B | $1.4B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ABT metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All ABT financial statements → Interactive ABT charts →
About TickerBase · Data methodology & sources